-
摘要: 目的:观察醛固酮受体拮抗剂螺内酯在阵发性心房颤动(房颤)复律后的治疗中,对血清醛固酮水平和左心房内径的影响,以及对窦性心律的维持作用。方法:选取阵发性房颤成功复律后的患者99例,随机分为治疗组(50例)和对照组(49例),对照组常规口服胺碘酮及福辛普利,治疗组在上述治疗的基础上再加服螺内酯20 mg/d,随诊1年,观察治疗前后血清醛固酮浓度、左心房内径及窦性心律的维持情况。结果:两组患者治疗后血清醛固酮水平[对照组(82.1±27.6)ng/dl,治疗组(79.7±32.5)ng/dl]较治疗前[对照组(145.2±37.1)ng/dl,治疗组(142.9±35.7)ng/dl]均明显下降(P<0.05),但两组间无显著差异(P>0.05)。治疗后治疗组的左心房内径(36.6±9.7)mm明显小于对照组(41.2±7.4)mm(P<0.05),且与治疗前相比[治疗组(45.5±9.2)mm,对照组(44.9±11.1)mm]均有显著缩小(P<0.01)。治疗组患者房颤平均发作次数(4.68±2.51)次明显少于对照组(7.20±5.46)次,治疗组窦性心律的维持率(77.1%)显著高于对照组(52.2%)(P<0.05)。结论:螺内酯对血清醛固酮水平无明显影响,但却可以在一定程度上延缓左心房的扩大,并能减少阵发性房颤的复发,提高窦性心律的维持率。Abstract: Objective:To observe the effect of spirolactone,the antagonist of aldosterone(ALD) receptor,on the plasma ALD level and left atrial dimension(LAD) in the treatment of paroxysmal atrial fibrillation (AF)after return to sinus rhythm.Method:Ninty-nine patients of paroxysmal AF were divided into control group and spirolactone group.All the patients took aminodarone 200 mg and fosinpril 10 mg per day orally.Besides,spirolactone group were given spirolactone 20 mg per day additionally.The plasma ALD level,the LAD and the rate of sinus rhythm maintenance were measured at before and after the therapeuticcourse of one year.Result:The plasma ALD level of both groups were lower than before,after one year of treatment.But there was no statistical difference between two groups(P>0.05).The LAD of spirolactone group was shorter than that of control group after one year(P<0.05),and the LAD of both groups were shorter than before(P<0.01).The rate of sinus rhythm maintenance of spirolactone group was higher than that of control group(P<0.05).Conclusion:Spirolactone has no effect on the plama ALD level,but can prevent atrial enlargement and reduce the recrudescence of AF.
-
Key words:
- spirolactone /
- aldosteroneatrial /
- atrial fibrillation
-
-
[1] BENJAMING E J, WOLF P A, D'AGOSTINO R B, et al.Impact of atrial fibrillation on the risk of death:the Frimingham Heart Study[J].Circulation, 1998, 98:946-952.
[2] 周自强, 胡大一, 陈捷, 等.中国心房颤动现状的流行病学研究[J].中华内科杂志, 2004, 43 (5):491-494.
[3] 中华医学会心血管病分会.中国部分地区心房颤动住院病例回顾性调查[J].中华心血管病杂志, 2003, 31 (8):913-916.
[4] 王学东, 贾三庆, 胡大一, 等.心房颤动患者循环血浆肾素、血管紧张素2和醛固酮的变化及临床意义[J].中国心血管杂志, 2004, 9 (5):339-341, 360.
[5] BERGLAND H, BOUKTER S, THEODORSSO E, et al.Raised plama concentrations of atrial natriuretic peptide are independent of left atrial dimensions in patients with chronic atrial fibrillationg[J].Br Hart, 1990, 64:9-13.
[6] 段徐, 来蕾.醛固酮与心房颤动[J].国际医学杂志, 2007, 5 (5):271-275.
[7] 陈明龙.心力衰竭与室性心律失常[J].中华心律失常学杂志, 2008, 12 (1):59-63.
[8] KAMY SHNIKOVA L A, EFREMOVA O A.Structural and functional changes in myocardium of patients with chronic heart failure treated with spironolactone[J].Klin Med (Mosk), 2012, 90:25-28.
[9] 谢永进, 王升起, 陈劲松, 等.醛固酮对人胎儿心脏成纤维细胞增殖以及胶原表达的影响[J].细胞与分子免疫学杂志, 2011, 27 (4):386-388.
[10] LIJNEN P J, VAN PELT J F, FAGARD R H.Stimulation of reactive oxygen specises and collagen synthesis by angiotensin in cardiac fibroblasts[J].Cardiovasc Ther, 2012, 30 (1):e1-8.
[11] KOSMALA W, PRZEWLOCKA-KOSMALA M, SZCZEPANIK-OSADNIK H, et al.Fibrosis and cardiac function in obesity:a randomized controlled trial of aldosterone blockade[J].Heart, 2013, 99:320-326.
[12] SCHOTTEN U, NEUBERGER H R, ALLESSIE M A, et al.The role of atrial dilatation in the domestication of atrial fibrillation[J].Prog Biophys Mol Biol, 2003, 82:151-162.
[13] FIORANELLI M, PICCOLI M, MILETO G M, et al.Modificationgs in cardiovascular functiongal parameters with aging[J].Minerva Cardioangiol, 2001, 49:169-178.
[14] 殷跃辉, 刘增长, 杨小渝, 等.小剂量与培哚普利联合治疗阵发性房颤的临床疗效[J].中国循环杂志, 2004, 19 (1):19-21.
[15] 顾红娟.依那普利与小剂量胺碘酮联合治疗阵发性房颤的临床观察[J].吉林医学, 2005, 26 (6):649-650.
[16] ROGERSON F M, YAO Y, SMITH B J, et al.Difference in the determinants of eplerenone, spironolactone and aldosterone bingding to the mineralocorticoid receptor[J].Clin Exp Pharmacol Physiol, 2004, 31:704-709.
[17] LU Y, KU E, CAMPESE V M.Aldosterone in the pathogenesis of chronic kidney disease and proteinuria[J].Curr Hypertens Rep, 2010, 12:303-306.
-
计量
- 文章访问数: 161
- PDF下载数: 132
- 施引文献: 0
下载: